ClinicalTrials.gg
CompletedNCT05232708Updated Jan 26, 2024

A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide

A Phase 1 interventional study of Semaglutide B, 1.34 mg/mL and Semaglutide D, 1.0 mg/mL in Healthy Volunteers (Diabetes Mellitus, Type 2), sponsored by Novo Nordisk A/S. Completed at 1 site in United Kingdom. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-26.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies testing semaglutide in Diabetes Mellitus — 12 open to participants now, 14 under way, 2 of them phase 3. Semaglutide · Diabetes Mellitus.

Enrollment
80th of 82
18 · median 100
Started
2022
with 3 others
Phase 1
36 of 82
none open now
Registered
66th of 82
by date
Lead sponsor
63 of 82
Novo Nordisk A/S

Among the 82 studies testing semaglutide in Diabetes Mellitus, this one is the 80th largest by enrollment, is one of 4 that started in 2022, is one of 36 in phase 1, and was the 66th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

12 of the 82 studies testing semaglutide in Diabetes Mellitus are open now, in 8 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 20 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies testing semaglutide in Diabetes Mellitus, or all of them as a file.
02

Study summary

In this trial, two approved solutions of the medicine semaglutide will be compared in healthy volunteers. The purpose of this trial is to see if semaglutide B and semaglutide D solutions are comparable with regards to moving into, through and out of the body when given in two separate injections. Participants will receive semaglutide B and semaglutide D in different periods of the trial (Period 1 and Period 2). Participants will receive 1 subcutaneous injection of semaglutide B (0.5 mg) and 1 subcutaneous injection of semaglutide D (0.5 mg). The trial will last for 87 to 120 days (about 3 to 4 months), depending on how long the screening period (2 to 28 days) and washout period (14 to 21 days) are. Participants will have a screening visit, followed by an in house stay (5 nights/6 days) and 9 visits for each period. Participants will have to fast for at least 6 hours overnight with only water allowed before receiving the trial medicine on the second day of in house stay (Day 1) in Period 1 and Period 2.

03

Conditions studied

  • Healthy Volunteers (Diabetes Mellitus, Type 2)

Browse trials for

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • Aged 20-55 years (both inclusive) at the time of signing
  • (BMI) between 25.0 and 34.9 kilogram per meter square (kg/m\^2) (both inclusive)

Exclusion criteria

Exclusion Criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using adequate method
  • Any disorder which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol
  • Use of prescription medicinal products or non-prescription drugs, except routine vitamins, topical medications, highly effective contraceptives and occasional use of paracetamol and acetylsalicylic acid, within 14 days prior to the day of screening
  • Abuse or intake of alcohol, defined as any of the below:

    • Known or suspected alcohol abuse within 1 year before screening (defined as regular intake of more than an average intake of 24 grams (g) alcohol daily for men and 12 g alcohol daily for women - 12 g of alcohol equals about 300 milliliters (mL) of beer or lager, 100 mL of wine, or 25 mL spirits).
    • Positive alcohol test at screening.
  • Abuse or intake of drugs, defined as any of the below:

    • Known or suspected drug or chemical substance abuse within 1 year before screening
    • Positive drug of abuse test at screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Semaglutide B, 1.34 mg/mL followed by Semaglutide D, 1.0 mg/mL

    Drug: Semaglutide B, 1.34 mg/mL · Drug: Semaglutide D, 1.0 mg/mL

  • Experimental
    Semaglutide D, 1.0 mg/mL followed by Semaglutide B, 1.34 mg/mL

    Drug: Semaglutide D, 1.0 mg/mL · Drug: Semaglutide B, 1.34 mg/mL

Interventions

  • DrugSemaglutide B, 1.34 mg/mL

    Drug page: Semaglutide

    Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.

  • DrugSemaglutide D, 1.0 mg/mL

    Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.

  • DrugSemaglutide D, 1.0 mg/mL

    Subjects will receive single dose of 0.5 mg Semaglutide D, 1.0 mg/mL subcutaneously.

  • DrugSemaglutide B, 1.34 mg/mL

    Drug page: Semaglutide

    Subjects will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.

06

What researchers measure

Primary outcomes

  1. AUC0-last,sema 0.5mg: Area under the semaglutide concentration-time curve from time 0 until last quantifiable measurement after single dose of s.c. semaglutide 0.5 mg

    Measured in h\*nmol/L

    Time frame: 0-840 hours after a single dose of s.c. semaglutide 0.5 mg

  2. Cmax,sema,0.5mg: maximum observed semaglutide concentration-time after single dose of s.c. semaglutide 0.5 mg administration

    Measured in nmol/L

    Time frame: 0-840 hours after a single dose of s.c. semaglutide 0.5 mg

07

Study locations

1 site
  • Parexel CPRU, Level 7
    Harrow, Middlesex HA1 3UJ, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Aug 2022, 7 months.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 7 months is above that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2022
First posted
Feb 10, 2022
StartActual
Jan 19, 2022
Primary completionActual
Aug 30, 2022
CompletionActual
Aug 30, 2022
Last update
Jan 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05232708
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 10, 2022
Start date
Jan 19, 2022
Primary completion
Aug 30, 2022
Completion
Aug 30, 2022
Last update
Jan 26, 2024

Study contacts

Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion